Evidence map›Paper›PMID 31632692›Full record

ArticleBDJ open2019

Variations in

L Otero, E Lacunza, V Vasquez, V Arbelaez, F Cardier, F González

Open access · goldAbstract read
In one paragraph

Article in BDJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Association between tooth agenesis and cancer: a systematic review.Journal of applied oral science : revista FOB · 2021
    Pooled it
  3. Article
  4. Article
  5. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Genotypes and Haplotypes in theBritish journal of biomedical science · 2022
    Article
  11. Article
  12. Article
  13. Wnt/β-catenin signaling in cancers and targeted therapies.Signal transduction and targeted therapy · 2021
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

L Otero1Dentistry and Sciences Faculties, Center of Dental Research, Pontificia Universidad Javeriana, Carrera 7 No. 40-62, Bogotá, Colombia.ORCID 0000-0003-1803-9141
E Lacunza2Medicine Faculty, Centro de Investigaciones Inmunológicas Básicas y Aplicadas (CINIBA), Universidad Nacional de La Plata, Calle 60 y 120, CP:1900 La Plata, Argentina.
V Vasquez3Dentistry Faculty, Pontificia Universidad Javeriana, Carrera 7 No. 40-62, Bogotá, Colombia.
V ArbelaezGastroenterology, Centro Médico Almirante Colón, Carrera 16. No. 84A-09, Bogotá, Colombia.
F Cardier3Dentistry Faculty, Pontificia Universidad Javeriana, Carrera 7 No. 40-62, Bogotá, Colombia.
F González5Dentistry Faculty, Universidad de Cartagena, Cra. 6 #36-100, Cartagena, Bolívar Colombia.
Pontificia Universidad Javeriana · COAsociación Colombiana de Gastroenterología · COUniversidad Nacional de La Plata · ARUniversity of Cartagena · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveColorectal cancer (CRC) and hypodontia are frequent and different diseases with common genes are involved in their etiology. The objective of this study was to identify the association between AXIN2 rs2240308 with hypodontia and CRC. PATIENTS AND

methodsThis study consisted of 50 individuals with hypodontia, 50 individuals with CRC, and 155 healthy individuals from Colombia. SNP genotyping assays of rs2240308 were performed and family history of cancer in individuals with hypodontia was documented

resultsAXIN2 rs2240308 showed association with CRC (OR = 5.4 CI: 2.7-10.4;

conclusionsThese results suggest that AXIN2 rs2240308 polymorphism is associated with CRC and AXIN2 could be a risk marker for predisposition and prognosis of CRC.

Indexed as

Cancer

Identifiers

PMID31632692
PMCPMC6795800
OpenAlexW2981087364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.